OncLive SOSS

The Evolving Treatment Paradigm for Stage I-IIIA NSCLC - Episode 8

Updates on Adjuvant Osimertinib for NSCLC Treatment from the ADUARA Trial

October 26, 2022

Heather Wakelee, MD, Bill W. Loo, MD, Ignacio I. Wistuba, MD, Jonathan Spicer, MD, PhD, Joshua Sabari, MD

Key opinion leaders share their thoughts on data updates from the ADUARA trial on the use of osimertinib as an adjuvant therapy for NSCLC.

Video Player is loading.

Current Time 0:00

Duration 0:00

Loaded: 0%

Stream Type LIVE

Remaining Time 0:00

EP. 1: Recommendations for Molecular Testing in Non-Small Cell Lung Cancer (NSCLC)

EP. 2: Molecular Testing in Early NSCLC to Guide Treatment Decision Making

EP. 3: Is There a Role for Liquid Biopsies in Early NSCLC?

EP. 4: Updates in the Treatment of Stage I-IIIA NSCLC

EP. 5: The Role of Neoadjuvant Therapy in Patients with Resectable NSCLC

EP. 6: Selecting Appropriate Patients with NSCLC for Neoadjuvant Therapy

EP. 7: The Role of Adjuvant Therapy in Patients with NSCLC

EP. 8: Updates on Adjuvant Osimertinib for NSCLC Treatment from the ADUARA Trial

EP. 9: Adjuvant Therapy in EGFR-Mutated NSCLC

EP. 10: NSCLC Molecular Testing Recommendations for Community Hospitals

EP. 11: Exciting NSCLC Data Updates from ESMO 2022

x